Inhibition of the JAK/STAT pathway by ruxolitinib, a JAK1/JAK2 inhibitor, showed promising anti-tumor activity in patients with advanced T cell malignancies, especially tumors with JAK/STAT pathway aberrations (7). Here, JAK1 is linked to neoplasm.